<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph" /><meta name="keywords" content="Darbepoetin; Darbepoetin; Aranesp preparations" /><meta name="IX" content="Darbepoetin; Aranesp preparations" /><meta name="IXM" content="Darbepoetin" /><title>DARBEPOETIN ALFA: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5886-darbepoetin-alfa.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5886-darbepoetin-alfa.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5886-darbepoetin-alfa.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 08 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5812-nutrition-and-blood.htm">9 Nutrition and blood</a> &gt; <a href="PHP5813-anaemias-and-some-other-blood-disorders.htm">9.1 Anaemias and some other blood disorders</a> &gt; <a href="PHP5877-drugs-used-in-hypoplastic-haemolytic-and-renal-anaemias.htm">9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a> &gt; <a href="PHP5880-erythropoietins.htm">Erythropoietins</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5880-erythropoietins.htm" title="Previous: Erythropoietins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5887-aranesp.htm#PHP5887-aranesp" title="Next: Aranesp®">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301064.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22839-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Darbepoetin</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="PHP5880-erythropoietins.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</p></div></li><li><a href="PHP5887-aranesp.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Aranesp®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins &gt; DARBEPOETIN ALFA</p></div></li></ul><ul><li><h3>BNF for Children (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13914-erythropoietins.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13918-darbepoetin-alfa.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DARBEPOETIN ALFA</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13919-aranesp.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Aranesp®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins &gt; DARBEPOETIN ALFA</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20270-f.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02824.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-D11.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; D</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D1694.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>DARBEPOETIN ALFA</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT"> see under Dose below</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="target-text: Epoetin alfa and beta cautions " href="PHP5888-epoetin-alfa-beta-theta-and-zeta.htm#PHP5889">Epoetin</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Contra-indications </h2> <p class="cT">see <a title="target-text: Epoetin alfa and beta contra-indications" href="PHP5888-epoetin-alfa-beta-theta-and-zeta.htm#PHP5890">Epoetin</a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Hepatic impairment </h2> <p class="cT">manufacturer advises caution</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">no evidence of harm in <em>animal</em> studies—manufacturer advises caution </p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">manufacturer advises avoid—no information available</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="target-block: Epoetin alfa and beta side-effects" href="PHP5888-epoetin-alfa-beta-theta-and-zeta.htm#PHP5891">Epoetin</a>; also, oedema, injection-site pain; isolated reports of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure (discontinue therapy)—see also <a title="target-block: Erythropoietin CSM advice" href="PHP5880-erythropoietins.htm#PHP5884">notes above</a></p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p>Symptomatic anaemia associated with chronic renal failure in patients on dialysis (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="PHP5880-erythropoietins.htm#PHP5882">MHRA/CHM advice</a>), <span class="cP">adult</span> and <span class="cP">child</span> over 11 years, <span class="cK">by subcutaneous</span><em> or </em><span class="cK">intravenous injection</span>, initially 450 nanograms/kg once weekly, adjusted according to response by approx. 25% at intervals of at least 4 weeks; maintenance dose, given once weekly <em>or</em> once every 2 weeks</p></li> </ul></div><div class="cR"><ul><li><p>Symptomatic anaemia associated with chronic renal failure in patients not on dialysis (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="PHP5880-erythropoietins.htm#PHP5882">MHRA/CHM advice</a>), <span class="cP">adult</span> and <span class="cP">child</span> over 11 years, <span class="cK">by subcutaneous</span><em> or </em><span class="cK">intravenous injection</span>, initially 450 nanograms/kg once weekly <em>or </em><span class="cK">by subcutaneous injection</span>, initially 750 nanograms/kg once every 2 weeks; adjusted according to response by approx. 25% at intervals of at least 4 weeks; maintenance dose, given <span class="cK">subcutaneously</span> or <span class="cK">intravenously</span> once weekly <em>or</em> <span class="cK">subcutaneously</span> once every 2 weeks <em>or</em> <span class="cK">subcutaneously</span> once every month</p></li>  </ul><div class="cF"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. When changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements. Adjust doses not more frequently than every 2 weeks during maintenance treatment</p></div></div></div><div class="cR"><ul><li><p>Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="PHP5880-erythropoietins.htm#PHP5882">MHRA/CHM advice</a>), <span class="cK">by subcutaneous injection</span>, initially 6.75 micrograms/kg once every 3 weeks <em>or</em> 2.25 micrograms/kg once weekly (if response inadequate after 9 weeks further treatment may not be effective); if adequate response obtained, reduce dose by 25–50%</p></li>  </ul><div class="cF"><div class="cE"><h3 class="cT">Note</h3> <p class="cT">Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy</p></div></div></div></div>   </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="PHP5887-aranesp.htm#PHP5887-aranesp" title="Aranesp®">Aranesp®</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5880-erythropoietins.htm">Previous: Erythropoietins</a> | <a class="top" href="PHP5886-darbepoetin-alfa.htm#">Top</a> | <a accesskey="]" href="PHP5887-aranesp.htm#PHP5887-aranesp" title="Aranesp®">Next: Aranesp®</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>